CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
Abstract Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev t...
Main Authors: | Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3767 |
Similar Items
-
Hypoxia-induced phenotypic transition from highly invasive to less invasive tumors in glioma stem-like cells: Significance of CD44 and osteopontin as therapeutic targets in glioblastoma
by: Masahiro Nishikawa, et al.
Published: (2021-08-01) -
Significance of Glioma Stem-Like Cells in the Tumor Periphery That Express High Levels of CD44 in Tumor Invasion, Early Progression, and Poor Prognosis in Glioblastoma
by: Masahiro Nishikawa, et al.
Published: (2018-01-01) -
Usefulness of an Image Fusion Model Using Three-Dimensional CT and MRI with Indocyanine Green Fluorescence Endoscopy as a Multimodal Assistant System in Endoscopic Transsphenoidal Surgery
by: Akihiro Inoue, et al.
Published: (2015-01-01) -
Clinical features and endoscopic findings of pituicytoma in the sellar region: A case report and review of the literature
by: Tomoharu Aki, MD, et al.
Published: (2019-06-01) -
Different activation of presupplementary motor area, supplementary motor area proper, and primary sensorimotor area, depending on the movement repetition rate in humans
by: Kunieda, Takeharu
Published: (2011)